PDCD1 and neoplasm: Our initial working hypothesis stated that targeting HDAC6 enzymatic activity could improve the therapeutic effect of anti-PD-1 by decreasing the up-regulation of immune-suppressive mediators such as PD-L1, PD-L2, B7-H3, and B7-H4 in tumor cells.